MBX Biosciences Announces Positive Phase 1 Multiple Ascending Dose Data for MBX 2109, a Long-Acting Parathyroid Hormone Peptide Prodrug, in Healthy Adults
September 11, 2023
Press Releases
MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
August 7, 2023
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
July 10, 2023
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
November 14, 2022
MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109
October 5, 2022
MBX Biosciences Announces Closing of Seed Funding
September 10, 2019